Headquartered in Bedford, Massachusetts, Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. Our proprietary technology is based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body that is essential to joint health and tissue function. Anika’s products range from orthopedic/joint health solutions led by Orthovisc® and Monovisc®; our multi- and single-injection treatments for osteoarthritis of the knee, to surgical aids in the ophthalmic and anti-adhesion fields. The company also offers aesthetic dermal fillers for the correction of facial wrinkles. Anika’s Italian subsidiary, Anika Therapeutics S.r.l., provides a complementary product and technology portfolio comprised of HA-based products in the orthopedics/joint health, advanced wound care and ear, nose and throat fields. Anika’s technology portfolio, including Anika Therapeutics S.r.l.’s subsidiary’s regenerative tissue technology, advances the company’s vision to offer therapeutic products that go beyond pain management to protect and restore damaged tissue. The company’s approach has enabled Anika to deliver long-term shareholder value by providing profitability and positive cash-flow, two rare characteristics for an entrepreneurial small-cap company that Anika intends to retain as it grows in the industry.
Jul 27, 2016
Anika Reports Second Quarter 2016 Financial Results
Events & Presentations
Jul 28, 2016 at 9:00 AM ET
Q2 2016 Anika Therapeutics Earnings Conference Call
Jun 9, 2016 at 5:30 PM ET
Singular Research 11th Annual Spring Select Conference